Population Pharmacokinetics Modeling of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)

The aim of this study is to achieve a reasonable and accurate dosage and reduce the risk of drug toxicity, using population modeling of Clopidogrel drug.

In this study 132 cardiovascular patient undergoing Percutaneous Coronary Intervention (PCI) and receiving clopidogrel treatment were collected. For pharmacokinetics modeling, we use Monolix v4.3.3 software. Pharmacokinetic parameters in our desired one-compartment model include ka 5.97 1/h, k (elimination rate constant) equal to 0.126 1/hr and V (distribution volume) equal to 21 liter.

Results showed that factors including genotype, alcohol and cigarette consumption, body activation, blood factors like serum creatinine, red blood cells and hemoglobin, and receiving concomitant drugs from ACEIs, nitrates, beta-blockers, statins and Aspirin may affect pharmacokinetics of Clopidogrel.

Keywords: Clopidogrel, Population Pharmacokinetics , Pharmacogenetics,